-+ 0.00%
-+ 0.00%
-+ 0.00%

CE-Ventures backs Oyster Therapeutics in USD 60 million Series A financing

PUBT·11/10/2026 11:27:13
Listen to the news
CE-Ventures backs Oyster Therapeutics in USD 60 million Series A financing
  • CE-Ventures, Crescent Enterprises' venture capital platform, invested in Oyster Therapeutics' USD 60 million Series A financing.
  • Oyster, formerly Kesmalea Therapeutics, develops targeted protein degraders focused initially on tau-driven neurodegenerative diseases, including Alzheimer's.
  • The financing will advance its oral, brain-penetrant tau degrader toward clinical development while supporting its proprietary SELFTAC protein degradation platform.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Enterprises Venture Capital published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.